sustained control by IGF1 signaling (Fig. 1C ). To identify cancer relevant, IGF-induced 1 4 0 lncRNAs, we sought to examine the alteration of these lncRNAs in The Cancer Genome Atlas 1 4 1 (TCGA) breast cancer data (http://cancergenome.nih.gov/). Of the 65 lncRNAs only 12 had a 1 4 2 "KNOWN" gene status by GENCODE meaning the annotation is identical to a known and 1 4 3 curated gene in Entrez and is reported in TCGA. Examination of the 12 lncRNAs in the TCGA 1 4 4 breast cancer data through the cBIO portal (35, 36) revealed that 11 of them have copy number 1 4 5 or gene expression alterations in a subset of breast cancer patients (Table 1) . Interestingly, the 1 4 6 dysregulation of one lncRNA, SNHG7, is enriched in a patient population with a poorer 1 4 7 prognosis. SNHG7 is altered in ~5% of all breast cancer tumors in TCGA (70 of 1105 samples; 1 4 8 SNORA43 and SNORA17 are the snoRNAs expressed in two of the introns of SNHG7 1 7 0 ( Fig. 2A and S3A ). After the snoRNAs are spliced out of the primary SNHG7 transcript they are 1 7 1 further processed to become functional snoRNAs. However, the mature SNHG7 transcript is 1 7 2 conserved among primates ( Fig. S3A ), highly and ubiquitously expressed ( Fig. S3B ), unlikely to 1 7 3 encode for a protein as indicated by low PhyloCSF(37) (negative for all 6 frames) and 1 7 4 txCDsPredict (576.00) scores (both visualized in UCSC Genome Browser), and is predicted to 1 7 5 be highly structured (Fig. S3C) suggesting it is noncoding and has biological functions 1 7 6 independent of the snoRNAs. Both 5' and 3' Rapid Amplification of cDNA Ends (RACE) 1 7 7 confirmed that there are at least two main REFseq annotated isoforms expressed in MCF7 cells 1 7 8 that differ by one intron ( Fig. 2A and Fig. S3A red and blue and S3D). In this report, the 5 exon, 1 7 9 4 intron isoform is referred to as SNHG7-I ( Fig. S3A red) and the 4 exon, 3 intron isoform is 1 8 0 referred to as SNHG7-NI ( Fig. S3A blue) . The 3 rd RefSeq SNHG7 isoform ( Fig. S3A no color) 1 8 1 was not detected by RACE. Subcellular fractionation followed by qPCR demonstrates SNHG7 is 1 8 2 predominantly expressed in the cytoplasm (Fig. 2B ).
8 3
To test the kinetic regulation of SNHG7 by IGF1, MCF7 cells were treated with IGF1 for 1 8 4 various lengths of time. The expression of SNHG7 is significantly and continuously down-1 8 5 regulated by IGF1 signaling for 24hrs ( Fig. 2C ). MCF7 cells were also treated with an IGF1R 1 8 6 kinase inhibitor (BMS-754807) and the expression of SNHG7 increased, further implicating that 1 8 7 the expression of SNHG7 is tightly regulated by IGF1 signaling (Fig. 2D ). This regulation is not 1 8 8 unique to MCF7 cells as SNHG7 is also regulated by IGF1 in the immortalized but non-1 8 9 transformed MCF10A cells ( Fig. 2E ). Additionally, there is a significant negative correlation (r=-1 9 0 0.2727;p<0.05) between RNA levels of SNHG7 and IGF1R ( Fig. 2F ) as determined by RNAseq 1 9 1 data published for a set of 56 breast cancer cell lines(38) reanalyzed through the pipeline 1 9 2 described above, suggesting the regulation of SNHG7 by IGF signaling is common in breast 1 9 3 cancer cell lines. 1 9 4
While mature SNHG7 is downregulated by IGF1 signaling, the snoRNAs contained 1 9 5 within the introns of SNHG7 are not significantly reduced ( Fig. 2G ), suggesting post-1 9 6 transcriptional regulation of mature SNHG7 instead of transcriptional regulation of the primary 1 9 7 transcript. To determine if this is the case, serum starved MCF7 cells were treated with 1 9 8
Actinomycin D before addition of IGF1 or vehicle. The inhibition of transcription did not ablate 1 9 9 the reduction of SNHG7 expression by IGF1 ( Fig. 2H ) suggesting that IGF1 alters SNHG7 2 0 0 expression by reducing the stability of the transcript and not through transcriptional repression. Actinomycin/Ctl) demonstrates transcription was effectively inhibited. Combined, these results 2 0 3 suggest that the regulation of the mature transcript is not merely a mechanism to change the 2 0 4 expression of the snoRNAs in the introns, but rather a tight regulation of the levels of the mature 2 0 5 SNHG7 lncRNA. 2 0 6 SNHG7 is a 5'terminal oligopyrimidine (5'TOP) gene similar to Gas5. It is known that 2 0 7
Gas5 lncRNA levels and other 5'TOP genes are destabilized by translation(39). Given that IGF1 2 0 8 signaling regulates translation, we tested if IGF1 regulates SNHG7 levels through translation. 2 0 9
Surprisingly, we observed that inhibition of translation with cycloheximide did not prevent IGF1 2 1 0 from decreasing the levels of SNHG7 ( Fig. 2I ), so we examined the effects of signaling 2 1 1 intermediates. Two of the primary downstream signaling pathways of IGF1R are 2 1 2 PI3K/AKT/mTOR and MAPK. Small molecule inhibitors of PI3K, MEK, and mTOR were used to 2 1 3 examine how IGF1 alters the stability of SNHG7. Inhibition of PI3K and mTOR had little effect 2 1 4 on IGF1's control of SNHG7 levels, while inhibition of MEK fully prevented alterations of SNHG7 2 1 5 levels by IGF1 signaling in serum starved MCF7 cells ( Fig. 2I ) indicating MEK signaling in the 2 1 6 destabilization of SNHG7. Collectively, these results ( Fig 2) suggest a novel mechanism 2 1 7
whereby IGF1 significantly down-regulates the expression of SNHG7 through posttranscriptional 2 1 8 alteration of SNHG7 mature RNA stability via the MAPK pathway. 2 1 9 2 2 0 SNHG7 is necessary and sufficient for breast cancer cell proliferation 2 2 1 IGF1 signaling regulates proliferation of breast cancer cells. To determine if SNHG7 has 2 2 2 similar effects, we examined the response of proliferation to altered SNHG7 levels. A pool of 2 2 3 independently designed siRNA duplexes significantly reduced mature SNHG7 expression 2 2 4 without altering the expression of the snoRNAs hosted in the introns (Fig. 3A ). The proliferation 2 2 5 of MCF7 cells with reduced SNHG7 expression was drastically reduced as scored by both a 2 2 6 fluorometric assay measuring DNA content ( Fig. 3B ) and by counting cells with a 2 2 7 hemacytometer using trypan blue exclusion ( Fig. S4A-B ). Proliferation of both other cell lines 2 2 8 examined, MDA-MB-231 ( Fig. S4C -D) and MCF10A ( Fig. 3C ) were also significantly reduced by 2 2 9
RNAi targeting SNHG7. The inhibition of proliferation in these cells is due to the reduction of 2 3 0 SNHG7 levels and not an off-target effect as demonstrated by the ability of 3 different individual 2 3 1 siRNA duplexes ( Fig. 3D ) that target SNHG7 to all inhibit proliferation ( Fig. 3E ). Interestingly, 2 3 2 these data suggest that there is a dose-dependent response to SNHG7 levels as the individual 2 3 3 duplexes that were most efficient at inhibiting SNHG7 levels also inhibited proliferation the most 2 3 4 ( Fig. 3D -E). A live/dead assay demonstrated that the reduction in cell numbers by siSNHG7 2 3 5 treatment is due to a decrease in proliferation ( Fig. S4E ) and not an increase in cell death ( Fig.  2 3 6 S4F). While control treated cells continued to increase in number, siSNHG7 treated cells do not 2 3 7 ( Fig. S4E) ; however, the number of dead cells is not significantly different between treatment 2 3 8 groups (Fig. S4F ). Additionally, FACS analysis with propidium iodine staining indicates that by 3 2 3 9 days siSNHG7 treated MCF7 cells begin to arrest in G0/G1 (Fig. 3F ). Reducing the expression 2 4 0 of SNHG7 had no effect on the sensitivity of MCF7 cells to the dual-kinase IGF1R/InsR inhibitor, 2 4 1 BMS-754807 ( Fig.S4G ). However, once again it is obvious that reduced SNHG7 expression 2 4 2 decreases basal proliferation ( Fig. S4G siCtl vs siSNHG7 at 10 -9 M). Together these data 2 4 3 demonstrate that SNGH7 is necessary for full proliferation of breast cancer cell lines.
4 4
To test if SNHG7 is sufficient to induce or enhance proliferation, the two main isoforms 2 4 5 of SNHG7 identified by RACE were cloned from cDNA of MCF7 cells. Two polyclonal MCF7 cell 2 4 6 lines stably expressing SNHG7 were generated for each isoform (Fig. 3G ) and non-linear 2 4 7 regression analysis of proliferation data demonstrated that MCF7 cells overexpressing either 2 4 8 isoform proliferated faster than cells expressing empty vector ( Fig. 3H ; doubling time=1.746-2 4 9 2.183 days for SNHG7 overexpressing cells vs. 2.684-2.89 days for empty vector cells 2 5 0 p<0.0001). Therefore, SNHG7 is both necessary and sufficient for proliferation and regulates it 2 5 1 in a dose-dependent manner. Furthermore, as described above, SNHG7 is overexpressed or 2 5 2 However, the METABRIC gene expression dataset was calculated by microarray analysis, 3 0 0 making it impossible to know the direct levels of SNHG7 and many other lncRNAs. For that 3 0 1 reason, we used a guilt-by-association technique to infer the levels of SNHG7 in each of the 3 0 2 patients. The top 100 upregulated and downregulated genes by siSNHG7, determined by fold 3 0 3 change with a FDR <0.05, were used as an 'SNHG7 signature' and a Gene Set Variation 3 0 4 Analysis(42) was performed to provide a score to each breast cancer tumor in the METABRIC 3 0 5 dataset. Kaplan-Meier analysis demonstrates that patients with tumors with the highest decile of 3 0 6 SNHG7 scores (indicative of high SNHG7 levels) have a significantly significant poorer disease-3 0 7 free survival (logrank test p-value=0.00079) than those with lower scores (Fig. S7 ). This further 3 0 8
argues that SNHG7 has an important biological and clinical role in breast cancer. 3 0 9 3 1 0
We leveraged the knowledge of IGF1 signaling and biology as a model system to identify a 3 1 2 lncRNA, SNHG7, that is important for proliferation and breast cancer biology. By doing so we 3 1 3 uncovered a novel fine-tuning feedback mechanism between IGF1 and SNHG7 that tightly 3 1 4
regulates RNA expression and cell proliferation. As summarized in a schematic in Figure 5 , our 3 1 5 data shows that in addition to the regulation of many protein coding genes, IGF, which is 3 1 6 necessary for proliferation, downregulates the expression of SNHG7. Our results also implicate 3 1 7 SNHG7 in the regulation of expression of an enriched set of IGF1-regulated genes and of IGF1 3 1 8 signaling intermediates (Fig. 5 left) . Additionally, there is a dose-response correlation between 3 1 9 SNHG7 levels and proliferation. Therefore, when IGF1 signaling is active it alters gene 3 2 0 expression (including downregulation of SNHG7) to increase proliferation (Fig. 5 middle) . 3 2 1 However, by reducing SNHG7, which regulates a similar set of genes as IGF1, and also 3 2 2 numerous IGF1 signaling intermediates, the amplitude of IGF1-regulated genes is muted ( Fig. 5  3  2  3 middle). When this feedback mechanism is overwhelmed, for example by the overexpression of 3 2 4 SNHG7 or the disruption of SNHG7 regulation by IGF1 (indicated by an x), it leads to enhanced 3 2 5 proliferation at least in part through differences in overall magnitude of IGF targets (Fig. 5 right -3 2 6 induced genes are expressed higher; repressed genes are repressed lower). 3 2 7
It is paradoxical that IGF1 would repress SNHG7, which controls the expression of many 3 2 8 of the same genes (in the same direction) and is necessary for proliferation, while 3 2 9 simultaneously inducing proliferation. However, our results and others(9) show that IGF1 3 3 0 signaling reduces the expression of IRS2, an immediate downstream signaling scaffold, and 3 3 1 increases the expression of numerous phosphatases (DUSPs) that dephosphorylate and 3 3 2 inactivate many of the kinases downstream of IGF1R. Thus, IGF1 regulation of SNHG7 3 3 3 expression is an example of a systems biology feedback mechanism to auto-attenuate IGF1 3 3 4 signaling. Further, our knock-down experiments that completely inhibit proliferation reduce 3 3 5 SNHG7 levels much lower than IGF1 signaling does (90% vs. 40%) suggesting there is a critical 3 3 6 amount of SNHG7 necessary for proliferation. Therefore, we propose that IGF1 regulates 3 3 7 SNHG7 levels as a feed-back mechanism to fine-tune the transcriptional response and 3 3 8 proliferation induced by IGF1 to prevent hyperproliferation or transformation/progression. If this 3 3 9
is true, we would predict that high levels of SNHG7 could lead to hyperproliferation. Accordingly, 3 4 0 SNHG7 is overexpressed or amplified in ~5% of TCGA breast cancer patients, and these 3 4 1 patients have worse disease-free survival than those without SNHG7 alterations. 3 4 2
In this report, we also describe a novel posttranscriptional mechanism of regulation of 3 4 3 SNHG7 through alterations in stability via the MAPK pathway. SNHG7 is a 5'TOP gene like 3 4 4
Gas5, which are regulated by nonsense mediated decay (NMD) through translation(43). While 3 4 5 SNHG7 levels are altered by mTOR and translational inhibition (data not shown), it is clear that 3 4 6 IGF1/MAPK regulation of SNHG7 levels is independent of translation induced by IGF1 because 3 4 7 inhibition of translation, mTOR, and PI3K/AKT did not prevent IGF1 mediated downregulation of 3 4 8 SNHG7. This suggests an additional mechanism of regulation of 5'TOP genes that requires 3 4 9 further investigation. 3 5 0
Our results that IGF-regulated lncRNAs, including SNHG7 and SNHG15, are important 3 5 1 for biology, enriched in breast cancer subtypes, and correlate with survival are consistent with 3 5 2 recent studies. A large number of functionally important lncRNAs were shown to be regulated by 3 5 3 estrogen signaling(25), but ours is the first study that examined regulation of lncRNAs by IGF. 3 5 4
Additionally, through reanalysis of TCGA data, others have demonstrated that certain lncRNAs 3 5 5 are enriched in specific breast cancer subtypes and lncRNAs alone can accurately stratify 3 5 6 patients into molecular subtypes (44) (45) (46) . In fact, lncRNAs were shown to be more subtype 3 5 7 specific than protein coding genes and some correspond to patient survival, suggesting their 3 5 8 utility as biomarkers (45). It is still unclear if SNHG7 or other IGF-regulated lncRNAs can be 3 5 9
used as biomarkers or targeted for therapy. However, further understanding of the IGF1/SNHG7 3 6 0 system, the mechanisms of SNHG7 functions, and the characterization of other IGF1-regulated 3 6 1 lncRNAs clearly will impact our understanding of both basic and breast cancer biology. pipeline used to identify persistently IGF1 regulated known lncRNAs. The Tuxedo package was 3 6 5 used to determine differentially expressed (DE) genes after IGF1 treatment. Novel gene 3 6 6 discovery was allowed, but for a conservative estimate only genes with Gencode V21 lncRNA 3 6 7 annotation that did not overlap with a protein coding gene (PCG) annotation on either strand are 3 6 8
reported. (B) Heatmap of the expression of lncRNAs (as defined in Fig. 1A ) significantly 3 6 9 regulated by IGF1 treatment at 3 or 8hrs. Expression levels are normalized to the mean of the 3 7 0 respective vehicle (Veh) control. Each column is a replicate of the indicated treatment group and 3 7 1 each row is an individual lncRNA (C) Venn Diagram demonstrating the number of lncRNAs 3 7 2 significantly regulated at 3hrs (blue), 8hrs (red), or both (purple). (D) SNHG7 is amplified or 3 7 3 overexpressed in a subset of the tumors of TCGA patients (N=45). Those patients have a worse 3 7 4
Disease Free Survival (Log-rank Test p<0.05) than patients with normal levels of SNHG7 DNA 3 7 5 and RNA (N=866). Patients with a copy number loss of SNHG7 (N=3) were ignored. (E) 3 7 6
Normalized RNASeq V2 RSEM expression data from annotated lncRNAs in TCGA breast 3 7 7 cancer (BC) data that are regulated by IGF at 3 and 8hrs was downloaded from the TCGA data 3 7 8
portal. Values were log2 transformed and then median centered by gene. Breast cancer 3 7 9 molecular subtypes determined by PAM50 scores (47) snoRNAs in SNHG7s introns determined by qPCR at 3 and 8 hrs. Levels were calculated as 3 9 9 described above and are reported as the mean expression +/-SD of biological triplicates. 4 0 0 (H-I) MCF7 cells were plated in triplicate for each treatment group, starved overnight, pretreated 4 0 1 with the indicated drug for 1-2hrs before stimulation with IGF1 or vehicle control for 8hrs. Cells 4 0 2 were harvested, RNA was isolated, cDNA was generated, and qPCR was performed and is 4 0 3 presented as described above. (H) 10ug/ml of actinomycin was used to inhibit transcription and 4 0 4 all results are normalized to the DMSO/Ctl group (I) 50uM of U0126 was used to inhibit MEK; 4 0 5 500nM of Wortmanin was used to inhibit PI3K; 1ug/ml of rapamycin was used to inhibit mTOR; 4 0 6 50 ug/ml of cycloheximide was used to inhibit translation; and, ctl was DMSO. Reported is the 4 0 7 mean +/-SD normalized to the respective Ctl. 4 0 8 4 0 9 transfected with three individual siRNA duplexes targeting SNHG7 or a non-targeting control 4 1 8 (siCtl) . RNA was isolated and qPCR was performed as described above to determine 4 1 9 knockdown of SNHG7. (E) Eight biological replicates of MCF7 cells were reverse transfected 4 2 0 with the three individual siRNAs for five days. Proliferation was measured as described above 4 2 1 and the mean +/-SEM for 8 biological replicates are reported. All results in D and E are 4 2 2 significant (ttests vs. siCtl <0.05). (F) MCF7 cells were reverse transfected in triplicate as 0 proliferation was scored with the FluoReporter (ThermoFisher) assay by quantitation of dsDNA 5 4 1 according to manufacturers' instructions on the Victor X4 (PerkinElmer). Proliferation was also 5 4 2 scored via counting cells with a hemocytometer (Fig. S4A) using Trypan Blue exclusion in 5 4 3 triplicate plated MCF7 cells in 6-well dishes. 5 4 4 Cell Cycle Assay: MCF7 cells were reverse transfected with siSNHG7, nontargeting control, or 5 4 5 nothing in biological triplicates. After 3 days, the cells were collected, fixed in 70% ethanol for 5 4 6 1hr, stained with 100ug/mL propidium iodide for 1hr, and then analyzed by flow cytometry. The 5 4 7 percentage of cells in each phase of the cell cycle was calculated according to protocol. 5 4 8 5 4 9
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